Whether you're new to exploring weight loss medications or seeking a knowledgeable partner in your weight management efforts, Klinic offers a comprehensive array of solutions to get you on the right track
Trends in Molecular Medicine, 11(9), 421-429
GLP-1 receptors are expressed on various immune cells, including T lymphocytes and macrophages, and preclinical research has identified potential anti-inflammatory effects of GLP-1 signaling, but the clinical significance of these observations remains uncertain
FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
Not everyone is a candidate, and that evaluation comes before any sourcing question
